Just a couple of years ago, generics were all the rage in pharmaceutical development programs. Big pharma companies scrambled for ways to create generics franchises that would enable them to offer a broad array of products to managed care customers. But now, with HMR's sale of its Rugby-Darby Group to Watson Pharmaceuticals, we seem to be in the midst of a major bail out. It's now clear that the smartest generics strategy is a no-generics strategy.
You may also be interested in...
A bill adopted by the US Senate marks the latest bipartisan move to tighten the country's grip over companies from China seeking an initial public offering, adding further uncertainty over such plans in the US.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.